Download Chief Investigators Flagship Lead

CINSW Goals for Translational Cancer Research Centres:
1. Facilitate the generation of practice improving research and its more rapid adoption
for improved patient outcomes.
2. Facilitate evidence into practice research.
3. Facilitate the more efficient and effective incorporation of research in:
 Clinical training
 Education
 Service delivery
Within formal governance structure that supports networks and enhanced
collaboration
4. Build capacity in research and improve competitive advantage in securing other
funds.
SYDNEY VITAL
Vision: Establish Sydney Vital as a competitive network of excellence in
conducting collaborative translational research to improve patient
outcomes.
Mission: Encourage and promote innovation and collaboration among
preclinical and clinical researchers to support cancer research across
the translational research pipeline.
SYDNEY VITAL GOALS
Making sure the right patient gets the right treatment at the right time and at the right cost
as a result of the translational research.
Self sustainable by 2019.
Enhance collaborations.
Develop and maintain essential research infrastructure.
Build a process to link the right people to do research.
Facilitate comprehensive research training and educational programs
Identify process disseminate research findings and support the implementation of evidence into practice
in an efficient manner.
Standardise process to identify right questions that align with health priorities.
Leverage funding opportunities and increase competitive advantage
Build a supportive governance structure
Sydney Vital Management Vision
SYDNEY VITAL TRANSLATIONAL Cancer RESEARCH PLAN
BASIC
SCIENCE
T3
T2
T1
TRANSLATIONAL
SCIENCE
CLINICAL
SCIENCE
IMPLEMENTATION
SCIENCE
CLINICAL
SERVICES
POLICY &
PRACTICES
Flagship 1
Flagship 2
Flagship 3
Flagship 4
Pillar 1
Pillar 2
Pillar 3
Pillar 4
Pillar 5
FUNDING
2014-2019
Centre Funding by CINSW
$ 5,836, 957
Centre Co-Funding by Usyd $ 1,000, 000
Centre Co-Funding by MCQ $ 150,000
80% research infrastructure and direct research support
20% admin (2.6FTE Administration)
Capacity Building
9 Research Scholars
5 Pillar initiatives
# Seed Funding
Research Infrastructure
SV supports 2.0 FTE Bio-banking Officers
Kolling biobank
Pathology research platform SV supports 0.3 FTE research pathologist.
Proteomics & Genomics Incl. next gen sequencing
Bioinformatics
SYDNEY VITAL RESEARCH PROGRAMS
Activity
Program
Alignment
Program Title
Flagship 1
Investigation of novel insulin-like growth factor (GF)-and sphingosine kinase
(sphK)-targeted-therapies for ER-negative, therapy-resistant breast cancer
(T1-T2)
Flagship 2
Professionalising the Multidisciplinary team Meetings in
Neureondocrine
Supervisor/
Leader
Awardees
Awarded
Amount
Period
Pillar 3
Prof Baxter
Dr Ochnik
$65,000
2014-2015
Pillar 1, 2 & 5
Prof Bailey
Dr Chan
$65,000
2014-2015
Prof Boyle
Dr Dhillon
$65,000
2014-2015
Tumours (T1-T2-T3)
Development and pilot implementation of an evidence-based clinical pathway
and toolkit for survivorship care in young women with breast cancer at high
Pillar 3 & 4
risk of stopping endocrine therapy prematurely (T2-T3)
Nano Medicine in Oncology: improved preoperative staging and better
Flagship 4
Pillar 1, 2, &3
understanding of chemotherapy delivery n (T1-T2-T3)
Alllocated to Flagship 4 to support the Nano Medicine project that is being
Seed Funding
developed
Pillar 1
Defining and achieving state of the art cancer diagnosis and treatment
Pillar 2
Determining why and when early stage cancer recurs
Pillar 3
Understanding and overcoming mechanisms of resistance in tumours
Pillar 4
Supportive Care, end-Stage Tumours, and end-of-life management
Pillar 5
Hereditary Cancer Syndromes
Noncoding RNAs as tumour suppressors in adrenal cancer: Unlocking the
Scholarship
mechanisms to improve patient outcomes.
A Role for p14ARF-p53 in Treatment Resistance and Recurrence in
Scholarship
Hormone-dependent Breast Cancer.
The bench-to-bedside clinical implementation of real-time targeted
Scholarship
radiotherapy for prostate cancer
Gene expression profiling of high-grade B-cell lymphomas with NanoString
nCounter technology. Validation of a novel diagnostic platform and
Scholarship
implementation into clinical use for prognostication and therapeutic decisionmaking.
Chemotherapeutic prodrugs incorporated within recombinant high density
Scholarship
lipoprotein nanoparticles as a modality of targeted delivery.
Scholarship
Currently being assessed
Scholarship
Currently being assessed
Scholarship
Currently being assessed
Scholarship
Currently being assessed
Flagship 3
A/Prof Engel & Prof
Dale Bailey
A/Prof Engel & Prof
Bailey
Prof Bailey
Dr Howell
Prof Marsh
Prof Boyle
A/Prof Gill
2015-2016
$80,000
$15,000
$15,000
$15,000
$15,000
$15,000
2014-2015
2014-2015
2014-2015
2014-2015
2014-2015
Prof Sidhu
Dr Glover
$15,000
2014-2015
Dr Nassif
Dr Hatoum
$15,000
2014-2015
Prof Keall
Dr Colvill
$15,000
2014-2015
Prof Stevenson
Dr Gifford
$15,000
2014-2015
Prof Smith
Dr Bulanadi $15,000
2014-2015
TBA
TBA
TBA
TBA
TBA
TBA
TBA
TBA
2014-2015
2014-2015
2014-2015
2014-2015
2014-2015
$15,000
$15,000
$15,000
$15,000
Total $485,000
Flagship 1
Investigation of novel insulin-like growth factor (IGF)-and sphingosine kinase
(SphK)-targeted therapies for ER-negative, therapy-resistant breast cancer (T1-T2).
Flagship Lead
Chief Investors
Rob Baxter
Stephen Clarke,
Debbie Marsh,
Fran Boyle,
Anthony Gill
Mark Molloy
R. Fellow
Aleksandra Ochnik
Proposal Title: Investigation of novel insulin-like growth
factor (IGF)- and sphingosine kinase (SphK)-targeted
therapies for ER-negative, therapy-resistant breast cancer.
Flagship 2
NETwork (multidisciplinary management of Neureondocrine Tumors (T1-T2-T3).
Flagship Lead
Dale Bailey
Alexander Engel
Stephen Clarke
Chief Investigators Anthony Gill
Debbie Marsh
R. Fellow
David Chan
Project Title: Professionalising the Multidisciplinary team
Meetings in Neureondocrine Tumours (T1-T2-T3)
Flagship 3
Development and pilot implementation of an evidence-based clinical pathway and toolkit for survivorship care in
young women with breast cancer at high risk of stopping endocrine therapy prematurely (T2-T3).
Fran Boyle
Flagship Lead
Chief Investigators
Debbie Marsh
Stephen Clarke
Mark Molloy
R. Fellow
Haryana Dhillon
Proposal Title: Development and pilot implementation of an
evidence-based clinical pathway and toolkit for survivorship
care in young women with breast cancer at high risk of
stopping endocrine therapy prematurely.
Flagship 4
Nano Medicine in Oncology: improved preoperative staging and better understanding of
chemotherapy delivery (T1-T2-T3).
Flagship Lead: Alexander Engel
CIs
Zdenka Kuncic
Ewa Goldys
Dale Bailey
R. Fellow
Robert Knox
Pillar 1
Defining and achieving state of the art cancer diagnosis and treatment.
Chief Investor
Dale Bailey
Pillar Leaders
Anubhav Mittal
Christopher Krisp
Pillar 2
Determining why and when early stage cancer recurs.
Chief Investor
Pillar Leaders
Viive Howell
Helen Wheeler
Nham Tran
Connie Diakos
Kelly Charles
Emily Colvin
Pillar 3
Understanding and overcoming mechanisms of resistance in tumours.
Chief Investor
Debbie Marsh
Pillar Leaders
Helen Wheeler
Nham Tran
Connie Diakos
Kelly Charles
Emily Colvin
Pillar 4
Supportive care, end-stage tumours, and end-of-life management.
Chief Investor
Pillar Leaders
Fran Boyle,
Josephine Clayton
Melanie Lovell
Pillar 5
Hereditary Cancer Syndromes.
Chief Investigator
Pillar Leaders
Anthony Gill
Mahtab Farzin
Angela Chou
Michelle Houang
Dr Crook (no picture)
SYDNEY VITAL LEAVERAGED FUNDS 2014-2015
Grant ID
Years
2012-2014)
Flagship Project
number (if
applicable)
2014-2015
Flagship 2
2014-2015
Flagship 2
ANSTO
2015-2019
2014-2015
Flagship 1&2
Flagship 2
Flagship 3
Amount
$
Chief Investigator
Funding Source
Novartis Pharmaceuticals
38,900 Australia Pty Ltd
16,500 PETNET Solutions
N/A
Alexander Engel & Nick Pavlakis
$
N/A
Alexander Engel & Dale Bailey
$
14/REG/1-10
Anthony Gill, Alexander….
$
750,000
N/A
Dale Bailey & Alexander Engel
$
16,500
N/A
Prof Boyle
$
100,000
Friends of the Mater
2014-2015
APP1081312
Pajic M., Timpson P., Gill A.J., Clarke S.J., Burgess A
Anderson RA, Swarbrick A, Johnstone R, Chua B, Gill AJ,
$
614,495
2015-2017
IF-14-01
Khanna KK, Lakhani S, Loi S, O'Toole SA, Saunders C
$ 1,745,270
NHMRC
National Breast Cancer
Foundation
201417
$
939,139
NBCF Accelerator
2014-2017
201418
M Lovell, J Phillips, M Agar, F Boyle et al.
P Francis, F Boyle, J Forbes, N Wilck en.ANZ Breast
Cancer Trials Group
$ 2,182,283
NHMRC Eliminate
2014-2018
N/A
L Pugliano, R Baxter, S Lord, F Boyle, S Twigg, J
Winstanley, M Stockler
$
N/A
Marsh DJ
$
N/A
Scott RJ, Hawkins N, Crowe P, Marsh DJ and Gedye C
$
CINSW Biobanking
265,000 Stakeholder Network
2014-2015
P Harnett, P Flynn and C Soon Lee
J Byrne, Marsh DJ, K Spring, RJ Scott, V Hodgkinson,
T Penna and I Gibson
$
CINSW Biobanking
266,524 Stakeholder Network
2014-2015
Pollock C, Marsh DJ, Hersey P, Howell VM and Sue C,
$
A deFazio, N Hawkins, CL Clarke, DJ Marsh, R Balleine,
N/A
PAM
CINSW
Ramsay Research and
8,000 Teaching Fund
2014-2019
60,000
2015-2015
DP140100137 Baxter RC
Baxter RC, Boyle FM, Martin JL
RG 15-21
$
CINSW Biobanking
134,520 Stakeholder Network
University of Sydney
NHMRC
Equipment Grant
55,000
390,000 ARC
$
360,000
Cancer Council NSW
2015-2017
Flagship1
Morris.J, Engel.A
$
750,000
NSW Health
2015-2017
Flagship1,2 and 3
N/A
N/A
$
TOTAL $ 8,692,131
2014-2015
2015-2015
2014-2016
SYDNEY VITAL PRESENTATIONS AND FUNCTIONS (JUNE-NOVEMBER)
Title
Date
Time
Location
Cancer Research Collaboration Forum
3-Jun-15
12-1pm
Kolling Institute
Cancer Genetics: Noncoding RNAs as biomarkers and therapy for adrenal cancerby Anthony Glover (PhD student).
Growth Research: Stimulatory effects of obesity on breast cancer progression:
Role of the IGF system by Tiffany Scully (PhD student)
Bill Walsh Laboratory: Emerging evidence for endothelial cells in the initiation of
human leukaemias - Indhu Subramanian (PhD student)
10-Jun-15
12-1pm
Kolling Institute
17-Jun-15
12-1pm
Kolling Institute
24-Jun-15
12-1pm
Kolling Institute
Lymphoma Update 2015, Continuing Education Series
14-Jul-15
6.30-9pm
Nilgiri's Restaurant
Cluster RCT to trial strategies for implementing the Cancer Pain guidelines- the
STOP Cancer Pain trial. By Dr Melanie Lovell
15-Jul-15
12-1pm
Kolling Institute
1st year anniversary for Sydney Vital
Multi-disciplinary teams (MDTs) - Workshop for basic researchers
21-Jul-15
TBC
TBC
18-Aug-15
TBC
Workshop: Implementing change through Multi-disciplinary teams (MDTs)
Sydney Vital Consumer/ Patients Forum
2015 Innovations in Cancer Treatment and Care Conference
17-Sep-15
6-Oct-15
15-Oct-15
TBC
Melanoma Institute
9am-4pm
Australia
3-7.30pm
TBC
8.30am-4.30pm UTS Function Centre
New Horizon in Prostate Care 2015, Continuing Edication Series
22-Oct-15
6-8.30pm
Nilgiri's Restaurant
Sydney Vital Collaborative Research Mini-Symposium
Gynaecological Cancer Update 2015, Continuing Education Series
17-Nov-15
11am-2pm
Kolling Institute
Jul/Aug 15
TBC
Nilgiri's Restaurant
"The tumour microenvironment in ovarian cancer". By Dr Emily Colvin Bill Walsh
Laboratory
“The impact of inflammation on cancer outcomes". By Dr Connie Diakos, Medical
Oncology
"Prostate radiotherapy research at RNSH – a move in the right direction". Assoc
Prof Andrew Kneebone, Radiation Oncology
“ TBA” Assoc Prof Rory Clifton-Bligh, Cancer Genetics
Sydney Vital Grant Station
Grant Calendar
Grant development
Ensuring projects are “grant ready”
Grant writing resources
Grant News and Updates